Kymera Therapeutics, Inc. research snapshot
KYMR AI stock analysis currently reads Kymera Therapeutics, Inc. as a clinical-stage biopharmaceutical company developing oral targeted protein degraders for immunological diseases. Its lead STAT6 program, KT-621, is in Phase 2b trials for atopic dermatitis and asthma, while the company had $1.55 billion in cash, cash equivalents, and investments at March 31, 2026 and expects runway into 2029. At the July 12, 2026 data cutoff, KYMR closed at $119.35 on July 10, implying a calculated market capitalization of about $9.82 billion using 82.26 million shares. This Kymera Therapeutics AI stock analysis uses scenarios, technical levels, and source-backed facts for information only. It is not investment advice.
Current price
$119.35
Market cap
$9.82 billion calculated from 82.26 million shares
AI score
57 / 100
Rating
Clinical-stage targeted protein degradation platform with strong cash runway and high clinical risk
Trend status
Long-term uptrend, short-term overbought and event-sensitive near resistance
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Kymera discovers and develops oral small molecule degraders, with wholly owned STAT6 and IRF5 programs plus partnered programs with Gilead and Sanofi. It has collaboration revenue but no approved product revenue. | High |
| Moat | The moat is based on target selection, degrader chemistry, discovery know-how, human-genetics-informed biology, patent families, and early clinical experience. It is a developing platform moat, not yet a commercial franchise. | Medium |
| Management | Founder, President, and CEO Nello Mainolfi has advanced the platform into Phase 2b and multiple partnerships. The team must now convert scientific differentiation into reproducible clinical and capital-allocation outcomes. | Medium |
| Financial trend | FY2025 collaboration revenue fell to $39.21 million from $47.07 million while net loss widened to $311.35 million. Q1 2026 revenue increased to $34.4 million, but net loss was still $69.2 million and R&D rose to $98.2 million. | High |
| Valuation | At $119.35, KYMR trades without meaningful PE or FCF support because FY2025 EPS was -$3.69 and FY2025 FCF was negative. The market value mainly reflects pipeline probability, platform optionality, cash, and future partnering or approval assumptions. | High |
| Technical trend | Price was above the 50-day average of $89.16 and 200-day average of $77.77, but RSI was 70.56 and the recent July range put resistance near $120 to $121. The setup is strong but extended. | Medium-high |
| Risk level | Risk is high because Kymera has no approved product, depends on clinical success, spends heavily on R&D, relies partly on collaboration milestones, and may experience large price moves around data and regulatory events. | High |
| AI confidence | Confidence is high for descriptive facts and calculations, but lower for price outcomes because clinical data can overwhelm technical and balance-sheet signals. | High data confidence |
| Investment certainty | The company has financial endurance and credible platform evidence, but actual investment certainty is low until KT-621 and the broader degrader pipeline clear important clinical hurdles. | Low-medium |
KYMR AI stock forecast
The KYMR AI stock forecast is a conditional scenario framework, not a price promise. The required three-scenario EPS command returned negative target prices because FY2025 EPS was -$3.69, so that output is not a useful intrinsic-value estimate. The ranges below are probability-sensitive market bands anchored to the $119.35 close, the cash runway, KT-621 milestones, and the possibility of clinical or valuation repricing.
$180 to $260
More likely if KT-621 produces strong BROADEN2 Phase 2b atopic dermatitis data by year-end 2026, advances toward Phase 3, KT-579 and KT-485 deliver clean early clinical data, Gilead and Sanofi partnerships generate further milestones, and the market continues to value the platform as a multi-indication opportunity.
$85 to $150
More likely if KT-621 data are mixed but usable, development continues through 2027, the cash runway remains intact, and collaboration revenue offsets only a portion of the large R&D base while the market applies a wide clinical-stage biotech range.
$35 to $70
More likely if KT-621 misses efficacy or safety expectations, later-stage programs fail to validate the platform, partners reduce commitments, cash burn accelerates, or investors assign a much lower probability to approval and require future equity financing.
KYMR AI technical analysis
KYMR AI technical analysis is constructive on the longer timeframe but stretched at the July 10, 2026 close. StockAnalysis showed a 50-day moving average of $89.16, a 200-day moving average of $77.77, RSI of 70.56, and average 20-day volume of about 1.32 million shares. Investing.com showed the latest close at $119.35, with recent highs near $120.60 to $120.90 and recent lows near $114.00 to $115.02. These technical readings are a snapshot at the July 12 cutoff and can change with the next session.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $119.35 | Investing.com historical close for July 10, 2026, the latest completed trading session before the July 12 cutoff. |
| Near support | $114 to $115 | The July 8 low was $114.03, the July 7 low was $115.02, and the July 10 low was $114.00. A close below this zone would weaken the immediate momentum structure. |
| Secondary support | $109 to $111 | The July 6 low was $111.21 and the June 29 to June 30 range reached $105.00 to $109.67. This is the next pullback area to monitor. |
| Near resistance | $120 to $121 | The July 7 high was $120.90 and the July 10 high was $120.60. A sustained close above this zone would mark a fresh breakout attempt. |
| Moving averages | SMA(50) $89.16; SMA(200) $77.77 | StockAnalysis snapshot updated July 10, 2026 showed price well above both rising long-term reference averages. The distance also shows that the trend has become extended. |
| Momentum | RSI(14) 70.56 | The RSI reading is near an overbought threshold. It can remain elevated during a strong trend and does not identify whether upcoming clinical news will be positive or negative. |
| Volume | About 1.32 million shares average over 20 days | StockAnalysis reported average 20-day volume of 1,319,201 shares. Compare breakout or breakdown volume with trial, licensing, and earnings headlines. |
| Volatility | High; beta 1.96 | StockAnalysis reported a five-year beta of 1.96. Clinical-stage biotech prices can gap beyond ordinary support and resistance levels. |
| Primary invalidation | Close below $109, then $89 | A decisive close below the $109 to $111 zone would weaken the recent swing structure. A break toward the 50-day average near $89 would require a broader thesis review. |
KYMR AI trading strategy
The KYMR AI trading strategy is a rules-based framework for a high-volatility clinical biotech. It is not personal advice and should be paired with live quotes, filings, position sizing, and a calendar of clinical, regulatory, and partnership events.
Watch for KYMR to hold the $114 to $115 area, reclaim or break the $120 to $121 resistance band with confirming volume, and remain above the rising 50-day average while no negative clinical update changes the thesis.
A close below $109 should invalidate the short-term swing setup. A move toward $89 should trigger a full review of the clinical thesis rather than an automatic dip-buying assumption.
If KYMR pulls back toward $109 to $115 without new safety or efficacy concerns, compare the price move with KT-621 trial timing, cash runway, partnership milestones, and the next disclosed data event.
Do not treat an oversold reading or a support touch as evidence that a clinical drawdown is temporary. Event-driven gaps can move through several technical levels.
Track KT-621 BROADEN2 atopic dermatitis data, BREADTH asthma progress, KT-579 Phase 1 data, KT-485 development with Sanofi, KT-200 milestones with Gilead, R&D spending, cash and investments, share issuance, and runway guidance.
Reduce confidence if the valuation depends on approval probability without new controlled data, if collaboration revenue becomes less reliable, or if cash burn shortens the stated runway.
Investment research summary
Kymera is trying to turn targeted protein degradation into oral medicines that remove disease-causing proteins rather than merely block them. Customers would pay only after clinical and regulatory proof shows that this mechanism improves outcomes, safety, convenience, or persistence versus existing immunology treatments.
The potential moat combines target selection, degrader chemistry, disease biology, proprietary discovery capabilities, patents, and a growing clinical dataset. It is not yet a proven commercial moat because no Kymera product has reached approval and competitors can pursue the same modality or disease targets.
The thesis fails if KT-621 does not reproduce Phase 1 signals in controlled Phase 2b trials, oral degradation creates safety or dosing problems, later programs lack therapeutic windows, partnerships do not produce durable economics, or cash burn and dilution overwhelm pipeline value.
Founder and CEO Nello Mainolfi has built a platform around immunology and advanced KT-621 into parallel Phase 2b programs. The June 2026 chairman transition to Felix Baker, with co-founder Bruce Booth remaining an independent director, shows a maturing board. The next management test is disciplined prioritization as clinical milestones multiply.
Targeted protein degradation is part of a broader shift toward medicines that address previously difficult intracellular targets. Kymera cites more than 140 million potential patients across Type 2 inflammatory diseases for STAT6, but the opportunity is only a market potential estimate until efficacy, safety, reimbursement, and differentiation are established.
At about $9.82 billion of equity value, KYMR has no earnings or free-cash-flow margin of safety because FY2025 EPS and FCF were negative. The balance sheet provides time, not intrinsic value. The current price therefore implies substantial confidence in KT-621, platform validation, partnerships, and eventual approval economics.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| KYMR latest completed-session price | $119.35 at the July 10, 2026 close | Investing.com historical data | July 12, 2026 |
| Market capitalization | $9.82 billion calculated as $119.35 x 82.26 million shares; reported market cap comparison variance 0.28% | StockAnalysis share snapshot and financial_rigor.py | July 12, 2026 |
| Shares outstanding reference | 82.26 million current share snapshot; the 2025 Form 10-K reported 81.642 million shares outstanding as of February 20, 2026 | StockAnalysis and Kymera 2025 Form 10-K | July 12, 2026 |
| FY2025 collaboration revenue | $39.21 million, versus $47.07 million in 2024 and $78.59 million in 2023 | Kymera 2025 Form 10-K, StockAnalysis, and Macrotrends | July 12, 2026 |
| FY2025 loss and EPS | Net loss of $311.35 million and diluted EPS of -$3.69 | Kymera 2025 Form 10-K and StockAnalysis | July 12, 2026 |
| Q1 2026 financial results | $34.4 million collaboration revenue, $98.2 million R&D expense, and $69.2 million net loss | Kymera Q1 2026 earnings release | July 12, 2026 |
| Cash and investments | $1.5457 billion at March 31, 2026; the company expects runway into 2029 | Kymera Q1 2026 earnings release and StockAnalysis balance sheet | July 12, 2026 |
| Lead pipeline milestones | KT-621 BROADEN2 Phase 2b enrollment completed with topline at year-end 2026; KT-579 Phase 1 data expected in 2H26; KT-485 Phase 1 initiated with Sanofi | Kymera 2026 press releases and pipeline | July 12, 2026 |
| Valuation snapshot | PE -32.34x, PB 6.37x, P/FCF -40.19x, FCF yield -2.49%, and FY2025 revenue per share $0.464 based on the audited calculation inputs | financial_rigor.py valuation verification | July 12, 2026 |
| Technical snapshot | SMA50 $89.16, SMA200 $77.77, RSI 70.56, average 20-day volume 1.32 million shares, beta 1.96 | StockAnalysis statistics and Investing.com historical data | July 12, 2026 |
This KYMR AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong if clinical results, financial results, regulation, partnerships, competition, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
